Oncotelic Therapeutics enters USD 178,410 convertible note financing with Pacific Pier Capital II
OTLC•Convertible note financing with Pacific Pier Capital II
On Aug. 3, 2026, Oncotelic entered the 2026 Pacific Pier SPA 2 with Pacific Pier Capital II, LP.
The company issued the 2026 Pacific Pier Note 2 with gross principal of $178,410; 12% original issue discount; and 12% annual interest.
The note converts at $0.06 per share or 85% of the lowest traded price over the prior 10 trading days.
It matures in one year unless prepaid or accelerated on an event of default; default interest rate is 16%.
Oncotelic also issued 500,000 common shares as commitment shares to Pacific Pier.
